The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
ELN Recommendations 2017 on Diagnosis and Management of Acute Myeloid Leukemia in Adults – Comments from Clara D. Bloomfield, co-author of the paper published in Blood*
Clara D. Bloomfield, MD, worldwide-recognized expert in AML was interviewed to provide her expert opinions on the new ELN recommendations. The transcripts are found below.
Why was it important to publish new European LeukemiaNet (ELN) recommendations on the Diagnosis and Management of Acute Myeloid Leukemia (AML)?
Was it specifically because of the new category “myeloid neoplasms with germline predisposition” in the new WHO classification?
Table 1: WHO classification of “myeloid neoplasms with germline predisposition” and guide for molecular genetic diagnostics
What are the new diagnostic procedure recommendations and when is molecular genetic testing included in the new diagnostic workup?
Table 2: 2017 European LeukemiaNet risk stratification by genetics
Which technique will be used to assess response: RT-qPCR (Real-Time Quantitative Polymerase Chain Reaction) or MFC (Multiparameter Flow Cytometry)?
You have included a new response criterion: CRMRD.?
Table 3: Response criteria in Acute Myeloid Leukemia
Will it be easy for hospitals to use this new response criterion?
You have established a new response criterion: “Progressive Disease”; can you explain why?
References